Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
Not yet recruiting · NCT07819591 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 2 | 2026-09-15 | NCT07819591 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Akesobio | 9 |
| Shanghai Yizhong Pharmaceutical Co., Ltd. | 3 |
| Shaodong Hong | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |